These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1201 related articles for article (PubMed ID: 31870275)
1. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion. Chen SC; Lo CM; Wang SH; Su EC BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275 [TBL] [Abstract][Full Text] [Related]
2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance. Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548 [TBL] [Abstract][Full Text] [Related]
3. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement. Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025 [TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
6. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
7. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193 [TBL] [Abstract][Full Text] [Related]
8. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071 [TBL] [Abstract][Full Text] [Related]
9. Easy-to-use machine learning system for the prediction of IDH mutation and 1p/19q codeletion using MRI images of adult-type diffuse gliomas. Nishikawa T; Ohka F; Aoki K; Suzuki H; Motomura K; Yamaguchi J; Maeda S; Kibe Y; Shimizu H; Natsume A; Innan H; Saito R Brain Tumor Pathol; 2023 Apr; 40(2):85-92. PubMed ID: 36991274 [TBL] [Abstract][Full Text] [Related]
10. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794 [TBL] [Abstract][Full Text] [Related]
11. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: Atypical molecular phenotype and current challenges in molecular diagnosis. Zheng L; Zhang M; Hou J; Gong J; Nie L; Chen X; Zhou Q; Chen N Neuropathology; 2020 Dec; 40(6):599-605. PubMed ID: 32761642 [TBL] [Abstract][Full Text] [Related]
12. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas. Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415 [TBL] [Abstract][Full Text] [Related]
13. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients. Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981 [TBL] [Abstract][Full Text] [Related]
14. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign. Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467 [TBL] [Abstract][Full Text] [Related]
15. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas. Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929 [TBL] [Abstract][Full Text] [Related]
16. Prediction of Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763 [TBL] [Abstract][Full Text] [Related]
17. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545 [TBL] [Abstract][Full Text] [Related]
19. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas. Yang X; Lin Y; Xing Z; She D; Su Y; Cao D Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488 [TBL] [Abstract][Full Text] [Related]
20. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]